Avexitide Reduces Severe Post Bariatric Hypoglycemia

Company Amylyx Pharmaceuticals Event Type Randomized Phase 3 results (LUCIDITY) Modality Peptide (GLP-1 receptor antagonist) Asset Avexitide Target GLP-1 receptor Disease Area Post-bariatric hypoglycemia Summary Amylyx detailed the randomized Phase 3 LUCIDITY trial: avexitide reduced the composite Level 2/3 hypoglycemic-event rate by 55% versus placebo…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *